Amendments to the Claims:

Please cancel Claims 4, 5, 15-21, 25, 26 and 36.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing:

- 1. (Original) A method for modulating the activity of a growth factor in a sample, which contains an activated α 2-macroglobulin, comprising (a) contacting the sample with a fatty acid in an amount sufficient to inhibit the formation of a complex between the growth factor and the activated α 2-macroglobulin, wherein (b) the fatty acid binds to the activated α 2-macroglobulin.
- 2. (Original) The method of claim 1 wherein the fatty acid has a carbon chain length of at least 14.
- 3. (Original) The method of claim 2 wherein the fatty acid is a saturated fatty acid.
- 4-5. (Canceled)
- 6. (Original) The method of claim 2 wherein the fatty acid is an unsaturated fatty acid.
- 7. (Original) The method of claim 6 wherein the fatty acid is selected from the group consisting of arachidonic acid, oleic acid, γ -linolenic acid, linoleic acid, palmitoleic acid and linolenic acid.
- 8. (Original) The method of claim 7 wherein the fatty acid is arachidonic acid.
- 9. (Original) The method of claim 1 wherein the growth factor is selected from the group consisting of platelet-derived growth factor-AA, platelet-derived growth factor-BB, vascular endothelial cell growth factor, fibroblast growth factors, interleukins, growth hormone, insulin, insulin-like growth factor-1, insulin-like growth factor-2, nerve growth factor, neurotrophins and TGF-β.

- 10. (Original) The method of claim 9 wherein the growth factor is TGF-β.
- 11. (Original) The method of claim 10 wherein the TGF- β is selected from the group consisting of TGF- β 1, TGF- β 2 and TGF- β 3.
- 12. (Original) The method of claim 11 wherein the TGF- β is TGF- β 1.
- 13. (Original) The method of claim 1 wherein the sample is a tissue or plasma.
- 14. (Original) The method of claim 13 wherein the tissue or plasma is in an animal.
- 15-21. (Canceled)
- 22. (Original) A method for modulating the activity of a growth factor in a sample, which contains an $\alpha 2$ -macroglobulin-growth factor complex, comprising (a) contacting the sample with a fatty acid in an amount sufficient to promote the dissociation of the $\alpha 2$ -macroglobulin-growth factor complex, wherein (b) the fatty acid binds to the $\alpha 2$ -macroglobulin portion of the $\alpha 2$ -macroglobulin-growth factor complex and (c) the growth factor dissociates from $\alpha 2$ -macroglobulin.
- 23. (Original) The method of claim 22 wherein the fatty acid has a carbon chain length of at least 14.
- 24. (Original) The method of claim 23 wherein the fatty acid is a saturated fatty acid.
- 25-26. (Canceled)
- 27. (Original) The method of claim 23 wherein the fatty acid is an unsaturated fatty acid.

- 28. (Original) The method of claim 27 wherein the fatty acid is selected from the group consisting of arachidonic acid, oleic acid, γ -linolenic acid, linoleic acid, palmitoleic acid and linolenic acid.
- 29. (Original) The method of claim 28 wherein the fatty acid is arachidonic acid.
- 30. (Original) The method of claim 1 wherein the growth factor is selected from the group consisting of platelet-derived growth factor-AA, platelet-derived growth factor-BB, vascular endothelial cell growth factor, fibroblast growth factors, interleukins, growth hormone, insulin, insulin-like growth factor-1, insulin-like growth factor-2, nerve growth factor, neurotrophins and TGF- β.
- 31. (Original) The method of claim 30 wherein the growth factor is TGF- β.
- 32. (Original) The method of claim 31 wherein the TGF- β is selected from the group consisting of TGF- β 1, TGF- β 2 and TGF- β 3.
- 33. (Original) The method of claim 32 wherein the TGF- β is TGF- β 1.
- 34. (Original) The method of claim 22 wherein the sample is a tissue or plasma.
- 35. (Original) The method of claim 34 wherein the tissue or plasma is in an animal.
- 36. (Canceled)
- 37. (Original) A method of blocking the inhibitory effects of activated $\alpha 2$ -macroglobulin on TGF- β activity or reversing the inhibitory effects of activated $\alpha 2$ -macroglobulin on TGF- β activity comprising (a) contacting a sample, which comprises an activated $\alpha 2$ -macroglobulin or an $\alpha 2$ -macroglobulin-TGF- β complex, with a fatty acid in an amount sufficient to (i) inhibit the formation of a complex between the TGF- β and the activated

 $\alpha 2$ -macroglobulin or (ii) promote the dissociation of the $\alpha 2$ -macroglobulin-TGF- β complex, wherein (b) the fatty acid binds to the activated $\alpha 2$ -macroglobulin or the $\alpha 2$ -macroglobulin portion of the $\alpha 2$ -macroglobulin-TGF- β complex.